National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Re-186 hydroxyethylidene diphosphonate
An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 hydroxyethylidene diphosphonate binds to hydroxyapatitie in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:186Re-etidronate
Re 186 hydroxyethylidene diphosphonate
rhenium Re 186 etidronate
rhenium Re 186 etidronate
Rhenium-186 HEDP
rhenium-186 hydroxyethylidene diphosphonate
Abbreviations:Re-186 HEDP
rhenium-186 HEDP



Previous:ras peptide cancer vaccine, rasburicase, ravuconazole, RayGel, razoxane
Next:Rebetol, Rebif, rebimastat, Recentin, recombinant 70-kD heat-shock protein

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov